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Disease in the Clinical Practice
Hildegard T. Greinix,1 Christoph Loddenkemper,2,3 Steven Z. Pavletic,4 Ernst Holler,5
Gerard Socie´,6 Anita Lawitschka,7 Joerg Halter,8 Daniel Wolff 5Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Devel-
opment Project proposed criteria for diagnosis and staging of both overall severity as well as organ severity of
chronic graft-versus-host disease (cGVHD) for use in clinical trials. In 2008, representatives of German and
Austrian allogeneic hematopoietic stem cell transplant (HSCT) centers established a study group on cGVHD
during the annual meeting of the GermanWorking Group on Bone Marrow and Blood Stem Cell Transplan-
tation (DAG-KBT) to intensify a dialog among HSCT physicians, pathologists, and medical consultants
focusing on the usefulness of the NIH consensus criteria for patient care in clinical practice and to promote
collaborations betweenHSCT centers as well as different medical specialities involved in HSCT.We first con-
ducted a survey of current practices of diagnosis, staging, and overall grading of cGVHD in daily clinical rou-
tine by sending an electronic questionnaire to the heads of the HSCT centers. During 3 meetings in 2009,
more representatives of allogeneic HSCT centers were included into the discussion process, resulting in
81% participation representing 88% of all allogeneic HSCT activities in Germany, Austria, and Switzerland.
During the third consensus meeting held in Regensburg, Germany, from November 6 to November 7,
2009, important agreements were achieved among participant having a strong impact on care of patients
with cGVHD. Areas of disagreement such as distinction between classical NIH cGVHD and overlap syn-
drome or assignment of liver GVHD after day 100 to acute or chronic category will be further assessed
in prospective observational studies among participants in the near future.
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6/j.bbmt.2010.07.017life [1-3]. It is a multisystemic disorder and can
present with a variety of clinical signs and symptoms
resembling autoimmune diseases such as scleroderma,
Sjogren’s syndrome, bronchiolitis obliterans, and
chronic immunodeficiency. The original descriptions
of cGVHD and its staging of severity were based on
small numbers of patients in the precyclosporine era
[4]. Recently, the National Institutes of Health (NIH)
consensus development project on criteria for clinical
trials in cGVHD established standardized criteria for
the diagnosis of cGVHDand proposed tools for scoring
cGVHD organ involvement and overall severity [5].
The recommendations of the NIH working group rep-
resent a consensus opinion based on leading interna-
tional HSCT expert assessments and evaluation of
peer-reviewed literature. The proposed methods and
tools for diagnosis and scoring of cGVHD, however,
have tobe validated inprospective studies. Furthermore,
their use in daily clinical routine has not been evaluated
yet with regard to their feasibility and accuracy because
they were established for use in clinical trials. In large
HSCToutpatient clinics routine assessmentof cGVHD
patients can be time-consuming and occupies valuable
and costly resources. cGVHD is a complex medical167
168 Biol Blood Marrow Transplant 17:167-175, 2011H. T. Greinix et al.condition, and patients’ care requires multidisciplinary
teams of physicians, nurses, pharmacists, psychosocial
personnel, and other clinical staff with specialized diag-
nostic and treatment units. Because patients with
cGVHD are at high risk for infections, organ toxicity,
and other life-threatening treatment-related complica-
tions for prolonged periods of time, a substantial num-
ber of prevention and monitoring strategies and
supportive care practices are already common and well
established in most HSCT units. Therefore, additional
diagnostic procedures, for example, for serial monitor-
ing of cGVHDpatients, couldpossibly put an enormous
additional burden on outpatient clinics and economic
constraints have to be considered.
In 2008, representatives ofGerman andAustrian al-
logeneic HSCT centers (see Appendix) established
a study group on cGVHD during the annual meeting
of the German Working Group on Bone Marrow and
BloodStemCellTransplantation (DAG-KBT) andfirst
conducted a survey of current practices of diagnosis,
staging, and overall grading of cGVHD in daily clinical
routine by sending an electronic questionnaire regard-
ing the use of NIH consensus definitions of acute
GVHD (aGVHD) and cGVHD,use ofNIHconsensus
scoringof organ-specificmanifestations and their sever-
ity, and prognostic criteria in daily clinical practice to
the heads of theHSCT centers. During 2009, the study
group on cGVHD expanded from the initial 21 HSCT
centers’ representatives to eventually 58 (81%) repre-
sentatives of allogeneic HSCT centers including also
Switzerland. The results of the survey as well as the
published NIH consensus documents were discussed
in 3 meetings with regard to acceptance or rejection
for daily clinical routine and in the final meeting held
in Regensburg, Germany, from November 6 to No-
vember 7, 2009, a consensus document was finalized.
The conferences were organized under the auspices of
theDAG-KBTand theGermanSocietyofHematology
andOncology (DGHO), theAustrian StemCellTrans-
plant Working Group, and the Austrian Society of
Hematology and Oncology (OEGHO), the Swiss
Blood Stem Cell Transplantation Group (SBST), and
the German-Austrian Paediatric Working Group on
Stem Cell Transplantation (PA¨D-AG-KBT). Of note,
pediatric aspects of the consensus document were also
discussed within a meeting of the PA¨D-AG-KBT in
fall 2009 and were accepted for daily clinical practice.
Results from these activities allow comment on
areas of agreement and controversy and identify areas
for future work.DESCRIPTION OF THE GERMAN/AUSTRIAN/
SWISS STUDY GROUP ON cGVHD
In the fall of 2008, physicians from the DAG-KBT
at an attending level position representing 21 allogeneicHSCT centers met in Wiesbaden, Germany, during
their annual meeting to discuss the recently published
NIH consensus criteria on cGVHD [5-8] with regard
to their feasibility in daily clinical patient care.
Participants decided to initiate a consensus consortium
on cGVHD with study groups on diagnosis and
staging, first-line therapy, salvage therapy, and sup-
portive care. To evaluate the current clinical practice
a questionnaire on diagnosis and stagingwas developed
by the study group that was sent electronically to the
medical directors of these 21 allogeneicHSCTcenters.
Within 4 weeks 13 of 21 (62%) responded and center
characteristics are shown in Table 1a. In further meet-
ings of the consensus consortium in March, June, and
November 2009, the number of participating centers
rose to finally 52 of 62 German (84%), 5/6 (83%)
Austrian, and 1 of 4 (25%) Swiss centers performing
88% of all allogeneic HSCT of their countries. Char-
acteristics of all responding and nonresponding centers
are shown in Table 1b. In addition, the consensus on
diagnosis and staging of cGVHDwas discussed within
the German-Austrian Paediatric Working Group on
Stem Cell Transplantation in the fall of 2009.RESULTS OF THE INITIAL SURVEYON DAILY
CLINICAL PRACTICE OF ALLOGENEIC HSCT
CENTERS
As shown in Table 2, 11 of 13 (85%) centers stated
to use the NIH criteria for diagnosis of cGVHD in
daily clinical routine. Ten (77%) also distinguished be-
tween classic NIH cGVHD and overlap syndrome. All
agreed with the NIH definition of classic cGVHD and
with the definitions of diagnostic and distinctive signs
of cutaneous cGVHD.Of note, only 5 (38%) routinely
performed skin biopsies for confirmation of cGVHD.
Whereas acceptance ofNIHdefinitions on cGVHDof
muscles, fascia, and joints was high among centers,
only 1 (8%) stated to routinely perform an electromy-
ography in case of muscle cramps. Acceptance of sever-
ity definitions both of organ manifestations as well as
overall severity of cGVHD among centers was high
as shown in Table 2. Only the definition of severity
of GI involvement had lower acceptance.
In addition, the survey asked about features of
cGVHD that are known risk factors for treatment-
related mortality (TRM), revealing a high acceptance
of thrombocytopenia at onset of cGVHD and progres-
sive onset of cGVHDas risk factors for patient outcome.AGREEMENT/DISAGREEMENTOF
PARTICIPANTS OF CONSENSUS MEETINGS
WITH NIH DEFINITION OF OVERLAP
SYNDROME
Currently, it is unclear whether pathophysiologic
mechanisms involved in classical cGVHD differ from
Table 1a. Characteristics of Centers Participating in Initial Survey (n 5 21)
Responding Centers N (%) Nonresponding Centers N (%) All Centers N
Number of centers 13 (62) 8 (38) 21
Number of centers with adult patients 12 (63) 7 (37) 19
Number of centers with pediatric patients 1 (50) 1 (50) 2
Number of alloHSCT per year 959 (68) 456 (32) 1415
Number of alloHSCTwith matched related donor per year 257 (68) 119 (32) 376
Number of alloHSCTwith unrelated donor per year 670 (68) 314 (32) 984
Number of alloHSCTwith cord blood per year 7 (70) 3 (30) 10
Number of alloHSCTwith mismatched related donor per year 25 (56) 20(44) 45
N indicates number; alloHSCT, allogeneic hematopoietic stem cell transplantation.
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one-third of participants in the consensus meetings felt
no need for distinction between these 2 subtypes in
daily clinical practice. In the discussions, the current
available evidence on prognosis of patients with over-
lap syndrome was presented. Jagasia and colleagues
[9] retrospectively reclassified 110 patients and re-
ported a significantly worse survival of patients with
any features of aGVHD after day 100 of HSCT com-
pared withNIH cGVHD. In a retrospective analysis of
54 consecutive patients, Arora and colleagues [10]
observed a significantly worse survival at 3 years in
patients with late, persistent, or recurrent aGVHD of
25% compared with 87% in patients with overlap syn-
drome and 75% in patients with classic NIH cGVHD.
Recently, Cho and colleagues [11] retrospectively
reclassified 211 patients who developed GVHD
more than 100 days after HSCT and observed 21%
late aGVHD, 30% overlap syndrome, and 49% classic
NIH cGVHD. Four-year GVHD-specific survival
was significantly different among patients with late-
onset, persistent, and recurrent aGVHD (100% versus
86% versus 56%, P 5 .009), but did not differ signifi-
cantly between overlap syndrome and classic NIH
cGVHD. Similar findings were reported by Vigorito
and colleagues [12] in 740 patients. Considering that
about 15% of patients with historic cGVHD may be
misdiagnosed and have late-onset, persistent, or recur-
rent (‘‘late’’) aGVHD, and that these patients have
significantly worse survival rates, a distinction between
late aGVHD and overlap syndrome seems very impor-
tant. Whether the outcome of patients with overlap
syndrome differs from the ones with classic NIH
cGVHD should be assessed in prospective studies.Table 1b. Characteristics of Centers Participating in Consensus Pr
Participating
Number of centers 58
Number of centers with adult patients 35
Number of centers with pediatric patients 23
Number of alloHSCT per year 2383
Number of alloHSCTwith matched related donor per year 655
Number of alloHSCTwith unrelated donor per year 1583
Number of alloHSCTwith cord blood per year 28
Number of alloHSCTwith mismatched related donor per year 117
N indicates number; alloHSCT, allogeneic hematopoietic stem cell transplanta
*In Innsbruck, only the pediatric HSCT program participated in the consensusTherefore, all participants of the German/Austrian/
Swiss consensus meetings eventually agreed on docu-
menting the category ‘‘overlap syndrome’’ separately
from classic NIH cGVHD, which is in agreement
with others suggesting proper stratification of patients
according to the NIH GVHD categories for their
inclusion in clinical trials [13].AGREEMENT/DISAGREEMENTOF
PARTICIPANTS OF CONSENSUS MEETINGS
WITH NIH DEFINITION OF LIVER
MANIFESTATIONS OF cGVHD
Hepatic cGVHDcan present as cholestasis with in-
creased bilirubin or alkaline phosphatase but also as
acute hepatitis with elevation of liver enzymes [14,15].
According to the NIH Consensus Development
Project liver biopsy is required to confirm GVHD
involvement of the liver [5]. In the survey, only around
half of all centers stated to perform liver biopsies in
case of isolated elevations of liver enzymes as shown
in Table 2. During the consensus meetings, various
clinical scenarios were discussed, and mainly lack of
response to immunosuppressive therapies and possible
concomitant infection were mentioned as indications
for liver biopsies in daily clinical routine. Because, ac-
cording to the NIH consensus, histologic similarities
between acute and chronic liver GVHD do not allow
to have a definitive diagnosis of chronic liver GVHD
when no other organ has a diagnostic or distinctive
sign of cGVHD [5,6], isolated elevations of liver
function tests remain challenging in daily clinical
practice. In the discussion among participants of the
German/Austrian/Swiss consensus meetings, it wasocess
Centers N (%) Nonparticipating Centers N (%) All Centers N
(81) 14 (19) 72
(74) 12* (26) 47*
(88) 3 (12) 26
(88) 331 (12) 2714
(86) 103 (14) 758
(89) 204 (11) 1787
(87.5) 4 (12.5) 32
(85) 20 (15) 137
tion.
process.
Table 2. Results of Survey on Daily Practice of Diagnosis and Staging of Chronic GVHD
Question No Centers in Agreement (%)
Do you use the NIH criteria for diagnosis of cGVHD in daily routine? 11 (85)
Do you distinguish between classic cGVHD and overlap syndrome? 10 (77)
Do you agree with the definition of classic cGVHD? 13 (100)
Do you agree with the definition of overlap syndrome? 12 (92)
At least 1 diagnostic sign* is necessary for diagnosis of cGVHD. 13 (100)
When a diagnostic sign* is missing, a distinctive sign with confirmation by lab,
radiology, or biopsy is required for diagnosis of cGVHD.
12 (92)
Do you agree with the diagnostic signs* of cGVHD of the skin? 13 (100)
Do you agree with the distinctive signs* of cGVHD of the skin? 13 (100)
Do you document the % of superficial sclerosis of the skin? 8 (61.5)
Do you document the % of deep sclerosis of the skin? 6 (46)
Do you document the % of hypo/hyperpigmentation of the skin? 3 (23)
We perform routinely skin biopsies in cGVHD patients. 5 (38)
Do you agree with the diagnostic signs* of cGVHD of the oral mucosa? 12 (92)
Do you agree with the distinctive signs* of cGVHD of the oral mucosa? 11 (85)
We routinely exclude infections of the oral mucosa. 9 (69)
Do you agree with the distinctive signs* of cGVHD of the eyes? 12 (92)
We routinely perform Schirmer tests. 4 (31)
Symptomatic patients are routinely seen by an ophthalmologist. 13 (100)
Do you agree with the diagnostic signs* of cGVHD of the genitalia? 11 (85)
Do you agree with the distinctive signs* of cGVHD of the genitalia? 11 (85)
Symptomatic patients are routinely seen by a gynecologist. 12 (92)
We routinely exclude infections of the genitalia. 3 (23)
Do you agree with the diagnostic signs* of cGVHD of the GI tract? 12 (92)
In symptomatic patients endoscopies are performed routinely. 11 (85)
In symptomatic patients endoscopic biopsies are performed routinely. 11 (85)
In case of weight loss resorption tests are performed routinely. 1 (8)
In case of diarrhea stool cultures are performed routinely. 13 (100)
In case of isolated elevation of liver function tests liver biopsies are done. 8 (61.5)
The diagnosis of cGVHD of the liver requires a distinctive sign in at least 1 other
organ system.
6 (46)
We routinely exclude viral infections in case of elevated liver function tests. 13 (100)
In case of elevated liver function tests ultrasound/CT scan of the liver is routinely
performed.
12 (92)
Do you agree with the diagnostic signs* of cGVHD of the lung? 9 (69)
Do you agree with the distinctive signs* of cGVHD of the lung? 10 (77)
We routinely perform pulmonary function tests after HSCT. 9 (69)
In case of decline of FEV1 an HR-CT scan is routinely performed. 12 (92)
In case of decline of FEV1 a BAL is routinely performed. 4 (31)
In case of possible BO lung biopsy is performed. 8 (61.5)
Do you agree with the diagnostic signs* of cGVHD of muscles/fascia/joints? 13 (100)
Do you agree with the distinctive signs* of cGVHD of muscles/fascia/joints? 11 (85)
In case of muscle cramps EMG is routinely performed. 1 (8)
In cGVHD pts tests for autoantibodies are routinely done. 7 (54)
Do you agree with the definition* of severity of cGVHD of the skin? 11 (85)
Do you agree with the definition* of severity of cGVHD of the oral mucosa? 12 (92)
Do you agree with the definition* of severity of cGVHD of the eyes? 13 (100)
Do you agree with the definition* of severity of cGVHD of the GI tract? 10 (77)
Do you agree with the definition* of severity of cGVHD of the liver? 12 (92)
Do you agree with the definition* of severity of cGVHD of the lung? 11 (85)
Do you agree with the definition* of severity of cGVHD of the joints? 13 (100)
Do you agree with the definition* of severity of cGVHD of the genitalia? 13 (100)
Do you agree with the definition* of mild cGVHD? 13 (100)
Do you agree with the definition* of moderate cGVHD? 12 (92)
Do you agree with the definition* of severe cGVHD? 13 (100)
Thrombocytopenia at onset of cGVHD is a risk factor for TRM. 11 (85)
Progressive onset of cGVHD is a risk factor for TRM. 12 (92)
>50% skin involvement by cGVHD is a risk factor for TRM. 10 (77)
No indicates number; HR-CT, high-resolution chest computed tomography; BAL, bronchoalveolar lavage; GI, gastrointestinal; EMG, electromyography;
TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplant; BO, bronchiolitis obliterans.
*According to [5].
170 Biol Blood Marrow Transplant 17:167-175, 2011H. T. Greinix et al.suggested to document liver involvement according to
the categories ‘‘Proven,’’ ‘‘Probable,’’ and ‘‘Possible’’
when isolated elevations of liver function tests such
as serum bilirubin or gamma GT are present in
a patient. Proven liver involvement could be defined
as histologic evidence of portal fibrosis, marked loss ofbile ducts, and chronic cholestasis with bile ductular
proliferation with or without bridging fibrosis that
reflects chronicity [6]. Probable liver involvement can
be considered in case of cholestasis with increased bil-
irubin or alkaline phosphatase and onset in close prox-
imity to discontinuation of immunosuppression and
Biol Blood Marrow Transplant 17:167-175, 2011 171Diagnosis of Chronic GVHD in Clinical Practicelack of concomitant infection or medication with
documented liver toxicity. Possible liver involvement
could be defined as presentation of elevated liver en-
zymes in close proximity to discontinuation of immu-
nosuppression or donor lymphocyte infusions but
indicates alternate diagnoses and reasons for suspicion.
Others suggested to document liver GVHD without
assignment to the acute or chronic category but with
further information such as time of onset of liver
GVHD after donor lymphocyte infusions or discon-
tinuation of immunosuppression. This would allow
an assignment retrospectively when the patient has
a longer follow-up and the course of GVHD becomes
more conclusive.
In view of the difficulties of distinguishing GVHD
from other diseases such as drug toxicities or infections
and the heterogeneous histologic presentations, a close
cooperation with a pathologist knowledgeable in liver
diseases including GVHD would improve our diag-
nostic arsenal substantially. It was agreed by all partic-
ipants that a cooperation on a national level with
reference pathologists should be established to im-
prove diagnosis of liver GVHD. A main indication
for liver biopsies is clinical refractoriness to immuno-
suppressive therapy allowing immunohistologic as-
sessment of extent of inflammation and bile duct
damage. Experience-based observations indicate that
the time to recovery after immunosuppressive treat-
ment is proportional to the degree of ductopenia [6]
and thus, immunohistologic results can support re-
sponse assessment. Besides verifying the diagnosis of
liver GVHD, other processes such as viral infections
or hemosiderosis can be excluded histopathologically.AGREEMENT/DISAGREEMENTOF
PARTICIPANTS OF CONSENSUS MEETINGS
WITH NIH DEFINITION OF LUNG
MANIFESTATIONS OF cGVHD
According to the NIH Consensus the only
diagnostic manifestation of lung cGVHD is biopsy-
proven bronchiolitis obliterans (BO) [5]. BOdiagnosed
via pulmonary function and radiologic testing (bron-
chiolitis obliterans syndrome [BOS]) requires at least
1 other distinctive manifestation in a separate organ
system to establish the diagnosis of cGVHD. In the
survey 9 (69%) centers stated to routinely perform pul-
monary function tests afterHSCTas shown inTable 2.
In the case of a decrease in forced expiratory volume in
1 second (FEV1), the vast majority of centers performs
high-resolution (HR) CT scans of the lungs but only
about a third stated to routinely perform a bronchoal-
veolar lavage (BAL). In the case of documented changes
consistent with BOS in chest HR-CT scans, the vast
majority of centers stated to perform a BAL but only
few of them considered a transbronchial biopsy mainly
to exclude infections or toxicities. Thus, during theGerman/Austrian/Swiss consensus meetings the dis-
cussions focused on screening of asymptomatic pa-
tients for early detection of cGVHD of the lungs
because only 7 (54%) centers participating in the survey
performed serial pulmonary function tests starting at
various time points and as late as 12 months after
HSCT, and few of them also included asymptomatic
patients. Critics of this policymentioned the additional
logistical and economical burden on HSCT facilities
by serial pulmonary function tests and were reluctant
to see their advantage for routine patient care. In sup-
port of serial pulmonary function tests Chien and col-
leagues’ [16] publication on an association of airflow
decline by day 100 after HSCT with a significantly
increased risk for development of transplant-related
airflowobstruction at 1 year afterHSCT in a retrospec-
tive cohort analysis of 1892 patients was presented
during the consensusmeetings.However, a singlemea-
surement of lung function on day 100was not sufficient
because airflow decline by day 100 was not associated
with an increased mortality risk and patients with fast
declines of FEV1 during the first year after HSCT ex-
perienced the highest mortality risk supporting repeat
pulmonary function tests after HSCT.
Recently, Gunn and colleagues [17] observed a sig-
nificant correlation of severity of air trapping on
HR-CT scans with changes in FEV1 measurements in
pulmonary function tests in BO patients after HSCT.
In the prospective German multicenter validation trial
on effect of cGVHD on quality of life and activity
profile, occurrence of BO at grade 2 according to the
NIHConsensus was significantly associated with worse
quality of life and activity profile of patients [18]. In view
of the highmortality rates of patients with BOS ranging
from 14% to 100% [16,19-21] and the option of
therapeutic intervention before irreversible pulmonary
damage evolves, all participants of the German/
Austrian/Swiss consensusmeetings eventually agreed on
performing serial pulmonary function tests starting
around day 100 after HSCT and being repeated every
3 months within the first year. Furthermore, in case
of a decrease in FEV1 by 20% compared to pre-
HSCT, chest HR-CT scan in expiration, and BAL
should be performed to exclude infections.
Of note, a modification of the NIH criteria on
lung involvement was proposed recently to diagnose
patients with earlier disease for interventions [22].AGREEMENT/DISAGREEMENTOF
PARTICIPANTS OF CONSENSUS MEETINGS
WITH NIH RECOMMENDATIONS ON OTHER
DIAGNOSTIC PROCEDURES AND
DOCUMENTATION IN DAILY CLINICAL
ROUTINE
For skin scoring of cGVHD the NIH Consensus
recommended documentation of percentage of affected
172 Biol Blood Marrow Transplant 17:167-175, 2011H. T. Greinix et al.body surface area (BSA) as well as superficial and deep
sclerosis [5]. This expert opinion consensus, however,
has not been validated yet. Other skin scoring systems
such as the total skin score validated by Greinix and
colleagues [23] and used in a randomized multicenter
phase II study in cGVHD patients [24] and the
Hopkins scale reported by Jacobsohn and colleagues
[25] were discussed during the consensus meetings.
Whereas a minority of centers initially reported
documentation of percentage of superficial and deep
hidebound sclerosis as shown in Table 2, further dis-
cussions during the consensus meetings let to a high
level of acceptance of the fact that proper documenta-
tion of both extent and quality of cutaneous
involvement by cGVHD at baseline and prior to ther-
apeutic changes is an important prerequisite for
response evaluation during and after topical and sys-
temic immunosuppressive therapy not only in clinical
studies but also in daily clinical practice.
Acceptance of diagnostic and distinctive signs of
oral mucosa involvement by cGVHD was also high
as shown in Table 2. However, only 9 (69%) centers
of the survey routinely excluded infections of the oral
mucosa in symptomatic patients.
During the consensusmeetings the validation study
of Elad and colleagues [26] revealing a strong correla-
tion between the total NIH score and both erythema
and ulcerations but no correlation between the scores
of the lichenoid/mucocele types and the scores of the
other types of oral manifestations and the evaluation
of inter-and intraobserver variability of NIH response
criteria scoring scale for oral cGVHD by Treister
and colleagues [27] using intraoral photographs were
discussed.
Pediatricians emphasized that children rarely
report dry mouth, taste alteration, and difficulties of
swallowing, and thus, a reduction of oral intake or the
need of increased drinking duringmeals could be often
the only symptoms of cGVHD of the oral mucosa. All
participants agreed on the importance of excluding in-
fections of the oral cavity by appropriate swabs in daily
clinical routine, and decided to incorporate these diag-
nostic procedures in their daily standards of care.
Although the vast majority of participants of the
German/Austrian/Swiss consensus meetings agreed
with the NIH definitions on eye involvement [5] very
few centers routinely performed Schirmer tests in their
patients as shown in Table 2. In further discussions,
including ophthalmologists, the need for close cooper-
ations with ophthalmologic specialists for both diag-
nostic procedures and topical therapies in daily
clinical routine was emphasized by all participants.
After thorough discussions the ophthalmologist com-
munity developed a standardized grading of severity
and criteria for response evaluation for daily clinical
routine that will be submitted by T. Dietrich and
colleagues as a separate manuscript for publication.In the survey 12 (92%), centers provided care by
a specialist for patients with cGVHD of the genitalia
but only 3 (23%) routinely excluded infections as
shown in Table 2. During further discussions among
participants of the German/Austrian/Swiss consensus
meetings the importance of these diagnostic proce-
dures was emphasized and accepted by all centers.
Whereas the vast majority of centers stated to
routinely perform endoscopies and biopsies in symp-
tomatic patients, only 1 (8%) referred patients to
resorption tests in case of weight loss as shown in
Table 2. During the consensus meetings currently
available diagnostic procedures in cGVHD patients
with weight loss and wasting syndrome were discussed
and incorporation of resorption tests into daily clinical
routine accepted by all participants.
During the German/Austrian/Swiss consensus
meetings the NIH gobal severity staging criteria that
have been preliminary validated for feasibility and
survival impact in several recent retrospective studies
[9,10,11,28] were discussed in detail and the vast
majority of participants agreed with them.PROGRESSIVE ONSET TYPE OF cGVHDAND
TRANSPLANTOUTCOME
Both in the survey as well as during the German/
Austrian/Swiss consensus meetings, the vast majority
of participants agreed with factors associated with
increased risk of TRMas stated by theNIHConsensus
[5]. In addition, participants mentioned that the NIH
expert opinion panel did not consider BOS and its
impact on TRM. During the consensus meetings, par-
ticipants discussed at length the differences and/or
similarities between overlap syndrome and progressive
onset of cGVHD with regard to impact on transplant
outcomes including TRM. In the original definition of
the Seattle group, cGVHDhad a progressive onset if it
followed aGVHDwithout resolution of aGVHD [29].
Several investigators demonstrated an association of
progressive onset with increased nonrelapse mortality
(NRM) in patients with historically defined cGVHD
[29-34].
Using the NIH scoring system Perez-Simon and
colleagues [28] recently reported significantly worse
survival of patients with severe NIH cGVHD and
progressive onset type. Vigorito and colleagues [12]
retrospectively reclassified 740 patients according to
the development of NIH cGVHD at the onset of
historically defined cGVHD or at any time afterward.
Antecedent late aGVHDwas associated with increased
risk of NRM among patients with NIH cGVHD. This
association corresponds with previous results showing
decreased survival among patients with a progressive
onset of historically defined cGVHD from aGVHD.
The authors speculated that antecedent aGVHD is as-
sociated with prolonged inflammatory insult to target
Biol Blood Marrow Transplant 17:167-175, 2011 173Diagnosis of Chronic GVHD in Clinical Practiceorgans, a greater degree of accumulated tissue damage,
and more profound immune dysregulation, making
subsequent NIH cGVHD more difficult to control
and contributing to increased risks of fatal infection
or organ failure [12].
When Arora and colleagues [10] retrospectively re-
classified 54 patients with cGVHD according to the
NIH consensus criteria the 20 patients (37%) with
progressive onset type turned out to have either late
aGVHD (n 5 5, 25%), classic cGVHD (n 5 4, 20%),
or overlap syndrome (n 5 11, 55%). Patients with late
aGVHD had a significantly higher TRM and signifi-
cantly worse survival, whereas no significant differences
between patients with classic NIH cGVHD and overlap
syndromewere observed.Thus, progressive onset type is
notnecessarily identicalwithoverlap syndromeandmost
likely includes a substantial number of patients with
aGVHD as reported by several investigators [9-12,35].
Thus, all participants of the German/Austrian/
Swiss Consensus conference agreed on documenting
both presence of aGVHD on day 100 after HSCT as
well as onset type of cGVHD to allow evaluation of
prognostic criteria of historically defined cGVHD
such as progressive onset type in cohorts of patients
studied prospectively with current day immunosup-
pressive and supportive care.CONCLUSIONS
cGVHD remains a source of significant morbidity
and mortality after allogeneic HSCT. Despite the
fact that the NIH consensus development project
proposed criteria for diagnosis and classification of
cGVHD for use specifically in clinical trials, these
criteria are very feasible for use in daily clinical prac-
tice. For both definitions of cGVHD, as well as overall
and organ specific severity staging, high rates of
acceptance were obtained among the vast majority of
allogeneic HSCT centers in Germany, Austria, and
Switzerland. In addition, medical consultants from
gastroenterology, pulmonary diseases, ophthalmol-
ogy, gynecology, and others agreed on the proposed
diagnostic procedures for establishing the diagnosis
of cGVHD and the severity scoring of affected organs
in HSCT clinical practice. Main topics of disagree-
ment among participants of the consensus meetings
were the importance of the distinction between classi-
cal NIH cGVHD and overlap syndrome and whether
isolated GVHD of the liver after day 100 after HSCT
should be considered as aGVHD or cGVHD. For
both areas, participants agreed on more detailed docu-
mentation of all future patients to allow prospective
multicenter studies assessing transplant outcomes.
Whereas the distinction between classical cGVHD
and overlap syndrome may not be clinically important
during routine monitoring of patients and their re-
sponse evaluation, the 2 different categories at onsetof cGVHDwill be evaluated prospectively in a registry
study regarding prognosis of patients including NRM
and survival. Purely clinical studies, however, will not
be able to resolve the question of whether isolated liver
abnormalities should be classified as late aGVHD or
NIH cGVHD. It is possible that blood biomarkers
or molecular studies of liver biopsies might yield
some information in that regard.
As a next step, the consensus group will establish
a cGVHD registry including staging and response
evaluation according to NIH criteria as a prerequisite
for observational studies within the consortium. Fur-
thermore, a network of reference pathologists is cur-
rently being established within Germany, Austria,
and Switzerland to improve the diagnostic yield of tis-
sue biopsies obtained from patients with cGVHD and
to discuss clinically related research projects on tissue
specimens. Moreover, the close cooperation with the
German/Austrian/Swiss consortium on cGVHD will
allow prospective sample collection for candidate
biomarker studies in the near future.ACKNOWLEDGMENTS
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INDIVIDUALS PARTICIPATED IN THE
CONSENSUS PROCESS:HSCT center(s) Name of Representatives Country
Survey and Consensus Conferences:
Berlin A. Gerbitz, L. Uharek Germany
Dresden A. Kiani Germany
Freiburg A. Bertz Germany
Hamburg A. Ayuk, U. Bacher, A. Zander Germany
Hannover M. Stadler Germany
Leipzig B. Basara Germany
Muenster M. Stelljes Germany
Oldenburg J. Casper Germany
Regensburg D. Wolff Germany
Rostock S. Hilgendorf Germany
Ulm S. v. Harsdorf Germany
Vienna* H. Greinix, A. Lawitschka Austria
Other Participants in Consensus Conference/Discussions:
Augsburg C. Schmid Germany
Berlin R. Arnold, M. Hildebrandt,
J. Kuehl, K. Rieger
Germany
Cologne C. Scheid Germany
Duesseldorf G. Kobbe, R. Meisel Germany
Dresden M. Suttorp Germany
Erlangen W. Roesler, W. Holter Germany
Essen A. Elmaagacli, B. Kremens Germany
Frankfurt am Main H. Martin, P. Bader Germany
Freiburg B. Strahm Germany
Giessen W. Woessmann Germany
Goettingen J. Hasenkamp Germany
Greifswald G. Doelken Germany
Hamburg H. Kabisch Germany
Hannover S. Buchholz, K. Sykora Germany
Heidelberg T. Luft Germany
Jena K. Schilling, K. Kentoche Germany
Kiel M. Gramatzki, A. Claviez Germany
Mainz R.G. Meyer Germany
Munich J. Tischer, M. Albert, I. Luettichau Germany
Muenster K. Ehlert Germany
Nuernberg S. Dressler, S. Wandt Germany
Regensburg R. Andreesen, E. Holler Germany
Stuttgart P. Schlegel Germany
Tuebingen W. Bethge, P. Schwarze Germany
Wiesbaden M. Schleuning, R. Schwerdtfeger Germany
Wuerzburg G. Stuhler Germany
Graz C. Urban Austria
Innsbruck† G. Kropshofer Austria
Linz O. Krieger Austria
Vienna Z. Kuzmina Austria
Basel J. Halter Switzerland
*In Vienna, 2 separate institutions (St. Anna Childrens’ Hospital and
Medical University of Vienna) participated in the survey.
†In Innsbruck, only the pediatric HSCT program participated in the con-
sensus process.
